Literature DB >> 12784033

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets.

Annika Olsson1, Eugeen Vanmechelen, Hugo Vanderstichele, Pia Davidsson, Kaj Blennow.   

Abstract

Accumulation of beta-amyloid (Abeta) in the brain is one of the central lesions in Alzheimer's disease (AD). Alternative cleavage of the amyloid precursor protein (APP), occurring in both normal and AD subjects, results in the generation and secretion of soluble APP, Abeta(40) and Abeta(42). Platelets have been regarded as the primary source of circulating APP and Abeta. Plasma levels of Abeta may therefore be dependent on platelet activation. We analysed Abeta(40/42) in plasma in the presence of physiological agonists of platelet activation such as adenosine diphosphate, collagen, thrombin, and a synthetic agonist, thrombin receptor activator peptide 6. We found that the levels of Abeta(40/42) in plasma were not related to platelet activation, suggesting that sampling techniques affecting platelet activation do not confound measurement of Abeta(40/42 )in plasma. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784033     DOI: 10.1159/000070681

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  2 in total

1.  The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay.

Authors:  D R Lachno; H Vanderstichele; G De Groote; V Kostanjevecki; G De Meyer; E R Siemers; M B Willey; J S Bourdage; R J Konrad; R A Dean
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.